

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**WEGO 威高**

**山東威高集團醫用高分子製品股份有限公司**

**Shandong Weigao Group Medical Polymer Company Limited \***

*(a joint stock limited company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1066)**

## **ANNOUNCEMENT**

### **PRINCIPAL FINANCIAL DATA OF WEIGAO ORTHOPAEDIC FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2021**

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Shandong Weigao Group Medical Polymer Company Limited (the “**Company**”) dated 29 October 2021 (the “**Announcement**”) in relation to the report for the third quarter ended 30 September 2021 (the “**Reporting Period**”) of Shandong Weigao Orthopaedic Device Company Limited (“**Weigao Orthopaedic**”), a subsidiary of the Company and whose shares are listed on the science and technology innovation board on the Shanghai Stock Exchange (stock code: 688161).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited financial data of Weigao Orthopaedic for the Reporting Period as set out in the Announcement.

\* For identification purpose only

## PRINCIPAL ACCOUNTING DATA AND FINANCIAL INDICATORS OF WEIGAO ORTHOPAEDIC

*Unit: Yuan  
Currency: RMB*

	<b>The Reporting Period (July to September)</b>	<b>Changes of the Reporting Period over the same period of last year</b>	<b>From the beginning of the year to the end of the Reporting Period (January to September)</b>	<b>Changes of the period from the beginning of the year to the end of the Reporting Period over the same period of last year</b>
Revenue	475,276,952.47	10.56%	1,570,592,770.80	24.47%
Net profit attributable to shareholders of the listed company	125,199,004.76	8.47%	494,349,485.99	29.00%
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	120,216,320.12	3.48%	484,384,368.40	32.33%
Basic earnings per share (Yuan/Share)	0.31	-2.76%	1.33	24.22%
Diluted earnings per share (Yuan/Share)	0.31	-2.76%	1.33	24.22%
Weighted average ROE	2.93	decreased by 2.28 percentage point	15.62%	decreased by 2.92 percentage points
			<b>From the beginning of the year to the end of the Reporting Period (January to September)</b>	<b>Changes of the period from the beginning of the year to the end of the Reporting Period over the same period of last year</b>
Net cash flow arising from operating activities			522,133,081.74	23.91%

	<b>At the end of the Reporting Period</b>	<b>At the end of last year</b>	<b>Changes of the end of the Reporting Period over the end of last year</b>
Total assets	5,145,963,866.16	3,174,596,918.79	62.10%
Equity attributable to shareholders of listed company	4,334,285,936.97	2,453,797,254.33	76.64%

By Order of the Board  
**Shandong Weigao Group Medical Polymer Company Limited**  
**Long Jing**  
*Chairman*

Weihai, Shandong, the PRC, 29 October 2021

*As at the date hereof, the Board comprises of:*

Mr. Long Jing (*Executive Director*)  
Mr. Cong Rinan (*Executive director*)  
Mr. Tang Zhengpeng (*Non-executive Director*)  
Mr. Chen Lin (*Non-executive Director*)  
Mr. Lian Xiaoming (*Non-executive Director*)  
Mr. Lo Wai Hung (*Independent non-executive Director*)  
Mrs. Fu Mingzhong (*Independent non-executive Director*)  
Mrs. Wang Jinxia (*Independent non-executive Director*)